Melanoma incidence has been rising steadily for decades, whereas mortality rates have remained flat. This type of discordant pattern between incidence and mortality has been linked to diagnostic drift in cancers of the thyroid, breast, and prostate. Ancillary tests, such as fluorescent in situ hybridization (FISH), are now being used to help differentiate melanomas from melanocytic nevi. Multicolor FISH has been shown to distinguish between these 2 with 86.7% sensitivity and 95.4% specificity. To assess the ability of FISH to differentiate melanomas with metastatic or lethal potential from those with an indolent disease course, we performed FISH with probes targeting 6p25, centromere 6, 6q23, and 11q13 on 144 primary melanomas with a minimal tumor thickness of 2 mm and compared the development of metastatic disease and melanomaspecific mortality as well as relapse-free and disease-specific survival between FISH-positive and FISH-negative cases. Of the melanomas, 82% were positive by FISH according to previously defined criteria. The percentage was significantly higher (93%) in cases that developed systemic metastases (n = 43) than in patients that did not (77%, n = 101). FISH-positive primaries had a significantly increased risk of metastasis or melanomarelated death compared with FISH-negative cases odds ratio 4.11; confidence interval, 1.14-22.7 and odds ratio 7.0, confidence interval 1.03-300.4, respectively. FISH status remained an independent parameter when controlling for known prognostic factors. These data indicate that the group of melanomas diagnosed with routine histopathology that lack aberrations detected by FISH is enriched for melanomas with a more indolent disease course. This suggests that molecular techniques can assist in a more accurate identification of tumors with metastatic potential.
H istopathologic assessment is the gold standard for the diagnosis of melanoma and allows for an unequivocal diagnosis in the majority of cases. However, there is a subset of melanocytic neoplasms, which cannot be reliably classified as benign or malignant using routine histologic evaluation. Multiple studies have shown diagnostic discordance rates for melanocytic neoplasms evaluated by routine methods ranging from 14% to 38% even among expert dermatopathologists. 4, 7, 13, 15, [18] [19] [20] Over the past few decades, the incidence of melanoma has increased continuously, whereas melanoma mortality rates have remained comparably constant. 21 This dichotomy is difficult to reconcile considering that no advances in melanoma therapy showing significant mortality benefit were made during this time period. Advances in melanoma treatment with BRAF inhibition and anti-CTLA4 therapy 8, 12 have occurred too recently to be counterbalancing factors. In addition, during this same time period, it has been noted that the increase in the diagnosis of melanoma parallels an increase in the number of skin biopsies. 22 A similar pattern has been observed in cancers of the thyroid, breast, and prostrate, in which incidences have also paralleled the number of diagnostic studies. 21 Although it can be argued that the lack of increase in mortality is due to removal of cancers at an earlier stage, thus preventing their progression to a lethal stage, this effect would result in a drop in mortality in subsequent years. Such an effect has not occurred. Instead, the data suggest that the increase in incidence is due to an increase of cases that are biologically indolent, which do not have metastatic potential. Diagnostic drift, a change in diagnostic criteria that results in classification of tumors as malignant that were previously classified as benign, is a likely contributing factor to this phenomenon. 14 Diagnostic drift leading to melanoma overdiagnosis is a significant problem as it leads to significant morbidity through unnecessary surgical and medical treatment, psychological trauma, and inflated health-care costs. We have recently described a panel of FISH probes, which detect common chromosomal imbalances in melanoma and distinguishes benign and malignant melanocytic tumors with 86.7% sensitivity and 95.4% specificity independent of histomorphology. 9 The diagnostic capability of this test in distinguishing nevi from melanomas has been validated in additional studies. 2, 3, 6, 10, 11, 16, 17 In this study, we analyze a cohort of unequivocal melanomas to determine whether clonal chromosomal imbalances detectable by FISH provide independent information that can identify tumors with metastatic potential.
MATERIALS AND METHODS
We retrieved paraffin-embedded tissue blocks of primary melanomas diagnosed before December 2007 measuring at least 2 mm in depth from the archives of the Oregon Health & Science University (OHSU) Dermatopathology Section and Pathology Department. All cases had an unequivocal pathologic diagnosis of melanoma and were independently reviewed in a blinded manner by a second dermatopathologist (R.M.). All studies were approved by the Institutional Review Boards at OHSU and University of California San Francisco. FISH analysis with probes targeting 6p25 (RREB1), centromere 6, 6q23 (MYB), and 11q13 (CCND1) was carried out as previously described. 9 Signals were scored according to previously determined criteria and thresholds 9 and were considered to be positive if 55% or more nuclei had higher 6p25 signal counts than Cep6 signal counts (6p imbalance), if 40% of nuclei had lower 6q23 signal counts than Cep6 (6q imbalance), if 29% or more nuclei had >2 signals for 6p25 (6p gain), or if 38% or more nuclei had >2 signals for 11q13 (11q gain). Clinical follow-up data were obtained from the OHSU tumor registry, medical record, and sentinel lymph node database.
Statistical Analysis
Fisher exact test and the Kaplan-Meier estimator were used to analyze FISH results in relation to diseasespecific survival (DSS) and disease-free survival (DFS). Fisher exact test and Wilcoxon rank sum test were used to test for significant associations between FISH results and established prognostic factors in melanoma. A Cox proportional hazards model was used for multivariate analysis.
RESULTS
One hundred forty-four melanomas were successfully analyzed by FISH, 118 (82%) of which tested positive by at least one of the 4 established criteria. 9 The pertinent clinical data and breakdown of melanoma subtypes included in the study are depicted in Tables 1  and 2 , respectively. Patients whose primary tumor tested positive tended to be older than patients with FISHnegative primaries (P = 0.049). No association between FISH status and other established prognostic factors such as sex, ulceration, tumor thickness, sentinel node status, and anatomic location was found ( Table 1 ). The median follow-up time was 32 months. A total of 43 (30%) cases had metastasized by the time of last follow-up, 40 (93%) of which tested positive by FISH. Twenty-seven patients died of melanoma, with all except 1 (96.7%) exhibiting chromosomal aberrations detected by FISH. By contrast, only 77% of patients that did not meet 1 of these 2 endpoints were FISH positive. These prognostic differences between FISH-negative and FISH-positive tumors were statistically significant (P = 0.02 for DSS and P = 0.04 for DFS). Three cases with stage IV (all IVc) disease were negative by FISH, one of which died from metastatic melanoma. Interestingly, the other 2 stage IV melanomas that were FISH negative had a complete response to interleukin-2 therapy with no evidence of disease at 32 and 34 months of follow-up. Patients whose primary melanoma tested positive for FISH had a significantly increased risk for the development of metastatic disease [odds ratio (OR), 4.11; P = 0.02; CI, 1.14-22.7] or death from melanoma (OR, 7.0; P = 0.04; CI, 1.03-300.4) compared with FISHnegative cases. Patients with FISH-positive primaries also showed a decrease in DSS and DFS by Kaplan-Meier analysis (Figs. 1, 2 , respectively) compared with FISHnegative cases. In a multivariate analysis controlling for sentinel lymph node status, tumor thickness, ulceration, and patient age, a positive FISH result was independently associated with increased risk for metastasis [hazard ratio (HR), 5.9; P = 0.04; CI, 1.06-32.44]. The trend was similar for independently predicting death from melanoma, but it fell short of statistical significance (HR, 5.7; P = 0.11; CI, 0.67-48.8).
We tested whether adjustment of the thresholds for signal counts of the 4 FISH probes could improve the discrimination between metastatic and nonmetastatic cases and determined the optimal combinations to distinguish metastatic tumors in this set of 144 melanomas (Table 3 ).
DISCUSSION
Similar to earlier studies, FISH analysis with probes targeting chromosomes 6 and 11 is negative in a minority of primary melanomas (18% in this study compared with 0% to 25% in other studies 2, 3, 6, [9] [10] [11] 16, 17 ). Several reasons may account for a negative FISH test result in histopathologically diagnosed melanomas. Not all melanomas have aberrations involving these 2 chromosomes, 1, 5 and it is therefore expected that the current FISH test misses such melanomas. This supposition is supported by the observation that the prevalence of aberrations involving the chromosomes enumerated by the assay can vary among biological variants of melanoma. For example, amplification of chromosome 11q13 is more common in melanomas arising on acral skin and skin with chronic sun-induced damage. 5 As shown in Table 2 , our study shows a distribution of subtypes similar to what would be expected for most US practices, and therefore includes a genetically diverse group of tumors.
Negative results will also be expected in melanocytic neoplasms that histopathologically simulate melanoma without having the malignant biological potential of a bona fide melanoma. The category of spitzoid melanocytic neoplasia is notoriously enriched for these cases due to lack of unequivocal histopathologic criteria for the distinction of spitzoid melanoma and neoplasms within the range of "atypical Spitz tumors." Our study of 144 melanomas included 6 spitzoid melanomas ( Table 2) . Independent histopathologic review confirmed the diagnosis of melanoma in all 144 cases with the exception of 1 of these 6 spitzoid melanomas, in which the possibility of an "atypical Spitz tumor" was raised (Fig. 3) . The Established criteria 9 >29% cells >55% cells >40% cells >38% cells Criteria to best predict metastatic potential in this study >28% cells >45% cells >55% cells >11% cells statistical results remained unaffected when this case was excluded from the analysis (risk for metastasis: OR, 5.73; P = 0.046; CI, 1.03-31.97 for univariate and HR, 4.51; P = 0.039; CI, 1.08-18.77 for multivariate analysis; melanoma-specific mortality: OR, 5.66; P = 0.042; CI, 0.71-45.28). Our findings raise the possibility that, in addition to the spitzoid group of melanocytic neoplasms, other types of melanocytic tumors that may appear to be melanoma by conventional histopathologic methods do not possess metastatic potential, 21 and that the absence of chromosomal aberrations may provide an opportunity to identify them. In this study, primary melanomas without chromosomal aberrations detectable by FISH for chromosomes 6 and 11 were significantly less likely to metastasize and cause death. The prognostic information of a positive FISH test was independent of sentinel lymph node status, tumor thickness, ulceration, and patient age, verifying that FISH detects unique prognostic features in melanoma. Our results, therefore, indicate that approximately 13% to 25% of melanomas that test negative by FISH contain a higher proportion of cases with lower metastatic risk, or conversely, that the assay's sensitivity for melanomas with metastatic potential is greater than for melanomas as a whole. We also found that the ability to predict future metastasis or DSS could be improved by modifying the previously established thresholds determined for assisting in the diagnostic distinction between nevi and melanoma. However, these thresholds will need to be independently tested in separate cohorts of melanoma to verify their validity. Limitations in this study include incomplete followup data in some cases. Owing to the nature of our tertiary-care center, some patients were only seen for sentinel lymph node biopsy with limited follow-up thereafter. In addition, we only tested melanomas with a minimum thickness of 2 mm to maximize the number of primary endpoints reached. Although it is expected that our results would apply to thinner melanomas, future studies are needed to verify this.
In summary, we found significant differences in the frequency of metastasis and DSS between FISH-positive and FISH-negative cases. The FISH test result yielded prognostic information predicting metastasis independent of tumor thickness and sentinel lymph node status. Our results, thus, suggest that a positive FISH test not only distinguishes melanomas from nevi with high specificity as previously shown, but also identifies melanomas with higher risk of metastasis. Conversely, although a negative FISH test cannot exclude a diagnosis of melanoma, it decreases the likelihood of one with metastatic potential. Future studies to confirm these results and explore additional FISH probes of potential prognostic value could increase the utility of FISH in detecting melanomas with metastatic potential. This would help identify patients who would benefit from more aggressive treatment and monitoring plans.
